This design enabled us to demonstrate that mean levels of anti-PTX3 antibodies were generally lower in most RA patients compared with those with FM and PsA, which may reflect better overall disease control and quality of life in RA [23]. This evidence concerns the gene PTX3 and rheumatoid arthritis.